Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report

Saki Sawayama; Ryusuke Murakami; Megumi Aki; Yusuke Kawaguchi; Yumi Takao; Hirofumi Nonogaki; Tomoyuki Goto; Chikako Yamauchi

doi:10.1016/j.gore.2022.100993

Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report

Gynecol Oncol Rep. 2022 May 2:41:100993. doi: 10.1016/j.gore.2022.100993. eCollection 2022 Jun.

Authors

Saki Sawayama¹, Ryusuke Murakami¹, Megumi Aki¹, Yusuke Kawaguchi¹, Yumi Takao¹, Hirofumi Nonogaki^{1

2}, Tomoyuki Goto^{3

4}, Chikako Yamauchi⁵

Affiliations

¹ Department of Obstetrics and Gynecology, Shiga General Hospital, Moriyama, Shiga, Japan.
² Department of Gynecology, Minamikusatsu Health Examination Centre, Kusatsu, Shiga, Japan.
³ Department of Gastroenterology and Hepatology, Shiga General Hospital, Moriyama, Shiga, Japan.
⁴ Department of Cancer Chemotherapy, Shiga General Hospital, Moriyama, Shiga, Japan.
⁵ Department of Radiation Oncology, Shiga General Hospital, Moriyama, Shiga, Japan.

Abstract

•We reported the use of pazopanib in the treatment of recurrent uterine carcinosarcoma with FGFR1 amplification.•The expert tumor board recommended pazopanib for off-label use based on genetic mutations found in cancer gene panels.•Pazopanib, a multi-tyrosine kinase inhibitor, was effective against recurrent uterine sarcoma with FGFR1 amplification.•Pazopanib maintained the patient's quality of life for a certain period.

Keywords: FGFR, Fibroblast Growth Factor Receptor; UCS, uterine carcinosarcoma.

Publication types

Case Reports